C91.3
Prolymphocytic leukemia of B-cell type
Clinical Classification Guidelines
Medical Intelligence & Overview
Prolymphocytic leukemia of B-cell type is a rare, chronic blood cancer that originates from B lymphocytes, which are a type of white blood cell crucial for immune response. Classified under ICD-10 code C91.3, this condition involves the abnormal growth of prolymphocytes, immature cells on the path to becoming mature lymphocytes. Unlike other leukemias, prolymphocytic leukemia has unique characteristics in its progression and response to treatment, often requiring specialized medical attention.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting the development of B lymphocytes Chromosomal abnormalities, such as deletions or translocations Environmental exposures to certain chemicals or radiation (though not well-established) A history of other plasma cell disorders or lymphoid malignancies (possible but not certain) Age-related changes, as it is more common in middle-aged and older adults
Key Symptoms: Persistent fatigue and weakness Unintentional weight loss Enlarged lymph nodes, especially in the neck, armpits, or groin Frequent or recurrent infections Fever or night sweats Easy bruising or bleeding due to low platelet counts Splenomegaly (enlarged spleen) Anemia symptoms such as pale skin or shortness of breath
Diagnostic & Treatment
Diagnosis Path: Blood tests: Complete blood count (CBC) often shows increased lymphocytes and other abnormalities Bone marrow biopsy: Confirms abnormal lymphocyte proliferation in the marrow Flow cytometry: Identifies the specific B-cell markers on abnormal lymphocytes Cytogenetic analysis: Detects genetic abnormalities associated with the disease Imaging tests: CT scans may be used to assess the extent of lymph node or organ involvement
Treatment Protocols: Chemotherapy: Uses drugs to reduce cancer cell growth and manage symptoms Immunotherapy: Employs medications that stimulate the immune system to target cancer cells Targeted therapy: Focuses on specific genetic mutations or proteins within the cancer cells Splenectomy: Surgical removal of the spleen may be considered in certain cases Supportive care: Includes blood transfusions, antibiotics for infections, and growth factors for blood cell production Clinical trials: Patients may have access to new treatments through research studies
Clinical Advice & FAQs
Billing Guidance
Is C91.3 a billable ICD-10 code?
Yes, C91.3 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C91.3?
Clinical documentation must specify the nature of Prolymphocytic leukemia of B-cell type and any associated comorbidities for accurate reporting.
Cite this Clinical Reference